Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Alternating Systemic and Hepatic Artery Infusion Therapy Versus Systemic Chemotherapy Alone As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer: A Randomized, Parallel-Group, Open-Labelled, Active-Controlled Phase II/III Trial in China

NCT02529774 is registered in ClinicalTrials.gov with Ye Xu as lead sponsor.

NCT NCT02529774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02529774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Alternating Systemic and Hepatic Artery Infusion Therapy Versus Systemic Chemotherapy Alone As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer: A Randomized, Parallel-Group, Open-Labelled, Active-Controlled Phase II/III Trial in China
Lead sponsor
Ye Xu
Phase
Phase 2/3
Overall status
Unknown status
Start date
September 30, 2015
Completion date
September 30, 2021
Enrollment
432 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resected liver metastases from colorectal cancer